Jump to:
Roquefort Therapeutics PLC Fundamentals
| Company Name | Roquefort Therapeutics PLC | Last Updated | 2025-06-27 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 157.444 m | Market Cap | £1.97 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.01 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0696 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.1763 | Cash Equity Ratio | 0.0690 |
|---|
| Quick Ratio | 0.6252 | Current Ratio | 0.63 |
|---|
| Price To Book Value | 0.4347 | ROCE | 0 |
|---|
Roquefort Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Roquefort Therapeutics PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|
| Tangible Assets | £44,748.00 | £50,152.00 | 0 |
| Intangible Assets | £5.34 m | £5.34 m | £5.34 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £5.39 m | £5.39 m | £5.34 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £25,380.00 | £157,589.00 | £101,738.00 |
| Cash & Equivalents | £337,112.00 | £537,322.00 | £2.32 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £5.75 m | £6.09 m | £7.77 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|
| Creditors within 1 year | £579,815.00 | £307,114.00 | £279,670.00 |
| Creditors after 1 year | £281,911.00 | £281,911.00 | £281,911.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £861,726.00 | £589,025.00 | £561,581.00 |
| Net assets | £4.89 m | £5.50 m | £7.21 m |
| Equity | 2024 | 2023 | 2022 |
|---|
| Called up share capital | £1.36 m | £1.29 m | £1.29 m |
| Share Premium | £4.62 m | £4.40 m | £4.40 m |
| Profit / Loss | -£1.21 m | -£1.93 m | -£1.63 m |
| Other Equity | £4.89 m | £5.50 m | £7.21 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £4.89 m | £5.50 m | £7.21 m |
| Ratios | 2024 | 2023 | 2022 |
|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.1763 | 1.1763 | 1.1763 |
| Cash / Equity | 0.0690 | 0.0690 | 0.0690 |
| EPS | -£0.01 | -£0.01 | -£0.02 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|
| Cash from operating activities | -£783,731.00 | -£1.73 m | -£1.58 m |
| Cashflow before financing | -£198,816.00 | -£1.73 m | £1.52 m |
| Increase in Cash | -£198,816.00 | -£1.79 m | £1.42 m |
| Income | 2024 | 2023 | 2022 |
|---|
| Turnover | 0 | £200,000.00 | 0 |
| Cost of sales | £16,000.00 | 0 | 0 |
| Gross Profit | -£16,000.00 | £200,000.00 | 0 |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | -£1.21 m | -£1.93 m | -£1.63 m |
Roquefort Therapeutics PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. The product portfolio of the company consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers. |
|---|
| Latest Interim Date | 27 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 30 Apr 2025 |
|---|
Roquefort Therapeutics PLC Directors
| Appointed | Name | Position |
|---|
| 2021-10-20 | Mr. Glenn Ross Whiddon | Non-Executive Director |
| 2025-04-30 | Mr. Stephen Paul West | Executive Director,Chairman |
| 2025-04-30 | Dr. Darrin Matthew Disley | Executive Director,Managing Director |
| 2022-05-11 | Mr. Mark Andrew Rollins | Non-Executive Director |
| 2024-05-23 | Dr. Michael Stein | Non-Executive Director |
| 2025-04-30 | Ms. Jean Duvall | Non-Executive Director |
| 2025-04-30 | Dr. Simon Sinclair | Non-Executive Director |
| 2025-03-17 | Professor Sir. Martin John Evans | Non-Executive Director |
| 2025-03-17 | Mr. Trevor Ajanthan Reginald | Executive Director,Chief Executive Officer |
Roquefort Therapeutics PLC Contact Details
Roquefort Therapeutics PLC Advisors
